Pharmacoeconomic analysis in various nosologies
Abstract
This article describes pharmacoeconomic analysis methods of which follow themodern requirements to this type of health technology assessment. Special attention is paid to the adaptation of pharmacoeconomic analysis methods to a specific nosology. The present paper demonstrates that each pharmacoeconomic study requires an individual approach, which takes into account both a specific disease peculiarities and the burden it poses on the patient, the community and the society.
About the Authors
A. A. Svistunov
I.M. Sechenov First MSMU
Russian Federation
Russian Federation
MD, Professor, First Vice-Rector – Vice-Rector for Innovation Policy and International Activities, I.M. Sechenov First MSMU.
45, Nakhimovsky prospect, Moscow, 117418
R. I. Yagudina
I.M. Sechenov First MSMU
Russian Federation
Russian Federation
Doctor of Pharmaceutical Science, Professor, Head of the Laboratory for Pharmacoeconomic studies, Pharmacy Research Institute, I.M. Sechenov First MSMU.
45, Nakhimovsky prospect, Moscow, 117418
G. T. Abdrashitova
I.M. Sechenov First MSMU
Russian Federation
Russian Federation
Guzel T. Abdrashitova - Postgraduate Student at the Laboratory of Pharmacoeconomic Studies, Pharmacy Research Institute, I.M. Sechenov First MSMU.
45, Nakhimovsky prospect, Moscow, 117418
Tel.: +7 (964) 572-74-32
V. V. Babiy
I.M. Sechenov First MSMU
Russian Federation
Russian Federation
Postgraduate Student at the Department of Organization of Medicinal Provision and Pharmacoeconomics, I.M. Sechenov First MSMU.
45, Nakhimovsky prospect, Moscow, 117418
E. I. Makarova
I.M. Sechenov First MSMU
Russian Federation
Russian Federation
Postgraduate Student at the Department of Organization of Medicinal Provision and Pharmacoeconomics, I.M. Sechenov First MSMU.
45, Nakhimovsky prospect, Moscow, 117418
A. A. Pochuprina
Scientific Center of Medical Expertise, Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
Postgraduate Student at the Scientific Center of Medical Expertise, Ministry of Health of the Russian Federation.
Yu. V. Rybchenko
I.M. Sechenov First MSMU
Russian Federation
Russian Federation
Postgraduate Student at the Department of Organization of Medicinal Provision and Pharmacoeconomics, I.M. Sechenov First MSMU.
45, Nakhimovsky prospect, Moscow, 117418
G. A. Tolordava
I.M. Sechenov First MSMU
Russian Federation
Russian Federation
Postgraduate Student at the Department of Organization of Medicinal Provision and Pharmacoeconomics, I.M. Sechenov First MSMU.
45, Nakhimovsky prospect, Moscow, 117418
D. T. Ugrekhelidze
I.M. Sechenov First MSMU
Russian Federation
Russian Federation
Postgraduate Student at the Department of Organization of Medicinal Provision and Pharmacoeconomics, I.M. Sechenov First MSMU.
45, Nakhimovsky prospect, Moscow, 117418
References
1. Bagirova V.L., Kolganova N.A, Razdobarin K.A. Relevance of pharmacoeconomic studies for pharmaceutical market optimization. Russian Biomed. J. Medline.ru. 2005; 6: 500–507 (in Russian).
2. Khabriev R.U., Kulikov A.Yu., Arinina E.E. Methodological basis of pharmacoeconomic analysis. Moscow: Medicine; 2011;128 (in Russian).
3. Yagudina R.I., Serpik V.G. On the possibility to combine budget impact analysis and cost-effectiveness analysis – development of «3D» pharmacoeconomic model. Pharmacoeconomics: theory and practice. 2014; 2 (3): 9–13 (in Russian).
4. Yagudina R.I., Babiy V.V. Methodological basics of health technologies effectiveness analysis in pharmacoeconomic studies. Pharmacoeconomics: theory and practice. 2015; 3 (1): 12–16 (in Russian).
5. Yagudina R.I., Serpik V.G., Sorokovikov I.V. Methodological basics of analysis of «cost-effectiveness». Pharmacoeconomics: theory and practice. 2014; 2 (2): 28–31 (in Russian).
6. Yagudina R.I., Kulikov A.Yu., Ugrekhelidze D.T. Assessing willingness-to-pay threshold for health technologies in the Russian Federation on the basis of purchasing power parity. Pharmacoeconomics: theory and practice. 2015; 3 (3): 10–14 (in Russian).
7. Yagudina R.I., Serpik V.G., Ugrekhelidze D.T. Methodological basis for budget impact analysis. Pharmacoeconomics: theory and practice. 2015; 3 (4): 9–12 (in Russian).
8. Abdrashitova G.T., Yagudina R.I., Serpik V.G. Pharmacoeconomic analysis of medical care for chronic renal disease patients in need of renal replacement therapy via peritoneal dialysis and hemodialysis in the Russian healthcare environment. Pharmacoeconomics: theory and practice. 2015; 3 (3): 111–117 (in Russian).
9. Yagudina R.I., Kulikov A.Yu., Koroleva N.I., Ugrekhelidze D.T. Pharmacoeconomics of spastic forms of cerebral palsy. Bul. of Scientific Centre for Expert Evaluation of Med. Products. 2015; 3: 60–64 (in Russian).
10. Ugrekhelidze D.T., Kulikov A.Yu. Pharmacoeconomic analysis of different types of treatment for spastic forms of cerebral palsy. Pharmacoeconomics: theory and practice. 2015; 3 (3): 71–78 (in Russian).
11. Tolordava G.A., Arinina E.E., Kulikov A.Yu. Pharmacoeconomic analysis of Fosinopril in patients with arterial hypertension. Pharmacoeconomics: theory and practice. 2016; 4 (1): 80–87 (in Russian).
12. Kulikov A.Yu., Komarov I.A., Pochuprina A.A. Pharmacoeconomic evaluation of targeted therapy in patients with systemic lupus erythematosus. Pharmacoeconomics: theory and practice. 2015; 3 (3): 98–102 (in Russian).
13. Kulikov A.Yu., Makarova E.I., Belevsky A.S. Pharmacoeconomic aspects of effective treatment of asthma Iziheyler. Practical pulmonology. 2015; 2: 57–60 (in Russian).
14. Rybchenko Yu.V. et al. Pharmacoeconomic analysis of use of specialized health food line «MDMIL PKU» in children from birth compared with diet therapy, started in later periods. Pharmacoeconomics: theory and practice. 2016; 4 (1): 44–52 (in Russian).
Review
Views: 42
Email this article 